AVGR vs. PAVM, GCTK, PETV, BTCY, NURO, INBS, VVOS, STSS, VAPO, and TMDIF
Should you be buying Avinger stock or one of its competitors? The main competitors of Avinger include PAVmed (PAVM), GlucoTrack (GCTK), PetVivo (PETV), Biotricity (BTCY), NeuroMetrix (NURO), Intelligent Bio Solutions (INBS), Vivos Therapeutics (VVOS), Sharps Technology (STSS), Vapotherm (VAPO), and Titan Medical (TMDIF). These companies are all part of the "surgical & medical instruments" industry.
Avinger (NASDAQ:AVGR) and PAVmed (NASDAQ:PAVM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, community ranking, profitability, earnings and analyst recommendations.
Avinger has a net margin of -251.78% compared to PAVmed's net margin of -2,037.67%.
In the previous week, Avinger had 1 more articles in the media than PAVmed. MarketBeat recorded 1 mentions for Avinger and 0 mentions for PAVmed. Avinger's average media sentiment score of 0.00 equaled PAVmed'saverage media sentiment score.
18.3% of Avinger shares are owned by institutional investors. Comparatively, 19.9% of PAVmed shares are owned by institutional investors. 11.4% of Avinger shares are owned by insiders. Comparatively, 12.6% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Avinger currently has a consensus target price of $5.00, suggesting a potential upside of 155.13%. PAVmed has a consensus target price of $21.00, suggesting a potential upside of 1,710.34%. Given PAVmed's higher probable upside, analysts plainly believe PAVmed is more favorable than Avinger.
Avinger received 192 more outperform votes than PAVmed when rated by MarketBeat users. However, 65.90% of users gave PAVmed an outperform vote while only 59.37% of users gave Avinger an outperform vote.
Avinger has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, PAVmed has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500.
Avinger has higher revenue and earnings than PAVmed. PAVmed is trading at a lower price-to-earnings ratio than Avinger, indicating that it is currently the more affordable of the two stocks.
Summary
Avinger and PAVmed tied by winning 8 of the 16 factors compared between the two stocks.
Get Avinger News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVGR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
